Patented Technology

TABMELT

Novel Patented Technology to Make Blockbuster Medications Better

TABMELT is a novel patented and patent-pending sublingual drug delivery system that allows patients to take a medication by simply dissolving a tablet under their tongue. This delivery route may lead to more instantaneous and accurate absorption than that of oral drug delivery.

TABMELT Biosciences Patents

Cardiovascular

Jurisdiction Compound Patent Status
United States VVRA – TM 001 Filed

Central Nervous System

Jurisdiction Compound Patent Status
United States VVRA – TM 002 Published
United States VVRA – TM 003 Filed
United States VVRA – TM 005 Published
United States PTNR – TM 006 Filed
United States PTNR – TM 007 Filed

Childhood-Onset Fluency Disorder (Stuttering)

Jurisdiction Compound Patent Status
United States VVRA – TM 008 Published
United States VVRA – TM 009 Pending

Oncology

Jurisdiction Compound Patent Status
United States VVRA – TM 004 Filed

Licensed TABMELT® Patents

Jurisdiction Title Patent Status
Australia All Natural, Non-Toxic Sublingual Drug Delivery Systems Issued, 2016
Canada All Natural, Non-Toxic Sublingual Drug Delivery Systems Issued, 2018
United Kingdom All Natural, Non-Toxic Sublingual Drug Delivery Systems Issued, 2018
Russia All Natural, Non-Toxic Sublingual Drug Delivery Systems Issued, 2021
Israel All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed
Japan All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed
Mexico All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed
United States All Natural, Non-Toxic Sublingual Drug Delivery Systems Published

MEDICAL & SCIENTIFIC LEADS

Dr. McColgan

Stephen J. McColgan, M.D. M.B.A.

Chief Medical Officer
  • 68 invited presentations, 12 publications
  • 35 years of surgical experience, 30+ years of experience in medical & surgical device development
  • Developed enhanced laparoscopic devices for a medical technology company, driving acquisition by a major publicly-traded company
  • Clinical instructor, professional consultant
  • Currently developing ZICOH and endomechanical devices for cardiovascular medicine and surgery
Dr. Maguire

Gerald A. Maguire, M.D., D.LF.A.P.A.

Chief Advisor, Neurosciences Division
  • Person who stutters and subject matter expert
  • 76 publications on stuttering—the most published doctor in the space
  • PI for the first investigational drug for stuttering in adults
  • Hundreds of invited presentations on stuttering
  • Professor of psychiatry, clinical trialist (PI of 40+ clinical trials for 25+ years)
  • Chair of R&D for World Stuttering Network
Bobby W. Sandage

Bobby W. Sandage, Jr., Ph.D.

Advisory Board
  • 3 patents issued, 50+ scientific articles 
  • 35+ years of experience in drug development, regulatory affairs, & life sciences venture capital 
  • Guided development for 35 products/programs
  • Achieved regulatory approval for 12 drugs and 1 device
  • Adjunct professor of pharmaceutical sciences
  • Drug Development Institute advisor for the Ohio State University Comprehensive Cancer Center
Kheriaty-2-1

Aaron Kheriaty, M.D.

Medical Ethics Advisor
  • 15 years of experience as a psychiatrist
  • Chairman of the medical ethics committee at the CA Department of State Hospitals
  • Professor of Psychiatry at the University of California, Irvine School of Medicine and Director of the Medical Ethics Program at UCI Health
  • Published in the Wall Street Journal and the Washington Post
  • Authored books and articles for professional and lay audiences on bioethics, social science, psychiatry, religion, and culture
MicrosoftTeams-image (44)

Fabio Macciardi, M.D., Ph.D.

Neurogenetics Scientific Advisor
  • Professor of Molecular Psychiatry at UCI, School of Medicine
  • Leads research focused on analyzing the function and evolution of neurocognitive genes and their associated traits
  • His lab identified more than 600,000 expressed discrete TEs in the human brain as major epigenetic regulators of gene expression in various neuropsychiatric disorders
  • Former VP and Director of Genetic Epidemiology and Bioinformatics at Genset SA (France)
Mehdi-Hatamian3264-1024x869

Mehdi Hatamian, Ph.D.

Chief Scientific Advisor
  • 120 patents issued, 50 published scientific papers 
  • 45+ years of engineering experience in the electrical and biomedical spaces
  • Chief Scientist of Central Engineering at Broadcom with a 20-year tenure
  • Former Program Engineer for the NASA Space Shuttle
  • Member of the National Academy of Engineering
  • Currently developing ZICOH and next-generation cancer detection devices and technologies

MILESTONES

September 15, 2016

TABMELT is Granted Australian Patent

TABMELT is issued Australian Patent No. 61/937,021 from IP Australia.

July 10, 2018

TABMELT Receives Canadian Patent

TABMELT is awarded Canadian Patent No. 2,888,219 from the Canadian Intellectual Property Office.

2018

TABMELT Receives United Kingdom Patent

TABMELT receives its United Kingdom Patent.

June 4, 2019

TABMELT Trademark Registration

TABMELT receives its trademark registration from the USPTO.

February 2021

TABMELT is Awarded Russia Patent

Vivera expands its exclusive global licensing of the novel TABMELT platform to Russia.

August 7, 2021

TABMELT Logo Trademark Registration

The TABMELT logo trademark is registered.

March 16, 2022

Vivera Executes LOI With NINDS of NIH

Vivera executes a letter of intent to enter a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to assess therapeutic agents for the potential treatments of stuttering disorders.

About Vivera

Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH, a smart dose-controlled electronic medical device. The Company has also received a Notice of Allowance for its portable telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Copyright © 2022 Vivera Biosciences. All rights reserved.